An experimental cell therapy seeks a different path for resistant melanoma
Advanced melanoma that no longer responds to immune checkpoint inhibitors remains a difficult setting for treatment development. A newly published pooled analysis examines amsokigene autoleucel, or amsoki-cel, an investigational tumor-infiltrating lymphocyte therapy designed for patients with immune checkpoint inhibitor-resistant advanced melanoma.
The treatment uses a patient’s own tumor-infiltrating lymphocytes, or TILs, engineered to express a membrane-bound form of interleukin-15. That IL-15 signal is designed to be regulated with acetazolamide, abbreviated ACZ. According to the study authors, this approach is intended to eliminate the need for interleukin-2 support, a feature that distinguishes it from TIL approaches that rely on administered IL-2.
The report combines results from two single-arm studies: a completed phase 1, single-center first-in-human trial and the ongoing multicenter phase 1/2 Agni-01 trial. The analysis is post hoc and was not prespecified, an important limitation when interpreting its findings.
What the pooled analysis covered
Across the two studies, 37 patients received lymphodepletion followed by varying doses and schedules of amsoki-cel and ACZ. Seventeen participants were treated in the first-in-human study and 20 in Agni-01.
The early portions of the trials were principally designed to assess safety, tolerability and to establish a recommended phase 2 dose. In the phase 2 portion of Agni-01, the primary objective is objective response rate at that recommended dose.
The treatment program did not proceed without an early safety signal. The first patient treated experienced rapid lymphocyte expansion and vasogenic edema involving a previously irradiated brain metastasis. That event prompted protocol changes and dose de-escalation in the first-in-human study. The maximum amsoki-cel dose was reduced by 80%, while the ACZ dose was reduced by 75%.
After preliminary safety was demonstrated at the lower dose, investigators increased doses in the first-in-human trial. Re-escalation was also initiated in Agni-01. The sequence illustrates the central task of early cell-therapy research: finding a dose and schedule that can support anti-tumor activity while managing the effects of a potent immune intervention.
Safety findings reported so far
In the pooled analysis, the researchers reported no dose-limiting toxicities, no intensive-care-unit care and no treatment-related deaths. Those observations are encouraging in a small, early-stage data set, but they are not equivalent to a definitive safety conclusion. The trials are single-arm studies, and the pooled analysis includes only 37 treated patients.
Hematologic adverse events were common. The most frequently reported treatment-emergent adverse events of grade 3 or higher were neutropenia in 24 of 37 patients, or 64.9%; leukopenia and lymphopenia in 21 of 37 patients each, or 56.8%; and anemia and thrombocytopenia in 14 of 37 patients each, or 37.8%.
Serious treatment-emergent adverse events were reported in 10 patients. Eight patients had serious events of grade 3 or higher. The paper reports grade 3 or higher non-hematologic serious events in five patients and hematologic serious events in five patients.
- 37 patients were treated across the two studies.
- No dose-limiting toxicities, ICU care or treatment-related mortality were reported in the pooled analysis.
- Severe blood-related adverse events were frequent and remain a major part of the therapy’s safety profile.
- An early serious event led investigators to reduce doses and amend the protocol.
Why the IL-15 design matters
Interleukin-15 is central to the therapy’s design because the engineered TILs carry a membrane-bound, ACZ-regulatable version of the cytokine. The stated goal is to provide a controllable support signal to the infused cells without requiring interleukin-2.
That design does not remove the need for careful monitoring. The initial case of rapid lymphocyte expansion and edema underscores why the investigators altered the regimen before later re-escalation. In early oncology studies, a treatment’s practical value depends not only on whether it can produce anti-tumor effects, but also on whether patients can receive it with an acceptable and manageable toxicity burden.
What comes next
The authors selected a recommended phase 2 dose using overall safety, tolerability and preliminary anti-tumor activity from phase 1 of Agni-01. The supplied report does not provide response-rate figures, durability data or comparative results. It therefore does not establish how amsoki-cel performs against other treatment options.
Still, the study provides an early look at a controllable, IL-15-engineered TIL strategy in a population with disease resistant to checkpoint inhibitors. The next meaningful evidence will come from continued evaluation at the recommended phase 2 dose, including the objective response-rate endpoint in Agni-01 and fuller reporting of efficacy and safety over time.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
